WO2023026245 - TREATMENT OF CLUSTER HEADACHE USING ANTI-CGRP ANTIBODIES
National phase entry:
Publication Number
WO/2023/026245
Publication Date
02.03.2023
International Application No.
PCT/IB2022/058002
International Filing Date
26.08.2022
Title **
[English]
TREATMENT OF CLUSTER HEADACHE USING ANTI-CGRP ANTIBODIES
[French]
TRAITEMENT DE LA CÉPHALÉE VASCULAIRE DE HORTON À L'AIDE D'ANTICORPS ANTI-CGRP
Applicants **
H. LUNDBECK A/S
Inventors
SPERLING, Bjorn
LARSEN, Frank
KLEWE, Ib Vestergaard
Priority Data
63/237,639
27.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2999 | |
| EPO | Filing, Examination, Granting | 12020 | |
| Japan | Filing, Examination, Granting | 2155 | |
| South Korea | Filing, Examination, Granting | 2071 | |
| USA | Filing, Examination, Granting | 5640 |
Total:
24,885
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Methods for treating cluster headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.[French]
L'invention concerne des méthodes de traitement de la céphalée vasculaire de Horton comprenant l'administration d'un anticorps antagoniste anti-CGRP à un patient nécessitant un tel traitement.